SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Dr. Reddy's Laboratories Ltd. (NYSE: RDY) and certain of its officers. Dr. Reddy’s operates as an integrated pharmaceutical company worldwide.
On November 6, 2015, Dr Reddy's reported that the Company received a "warning letter" from U.S. regulators over inadequate quality controls at three manufacturing plants producing drugs for cancer and other diseases.
Dr Reddy's said the FDA warning meant it would not receive U.S. approvals for drugs made at the plants until it fixed the problems. The manufacturing plants account for more than 10 percent to 12 percent of Dr. Reddy's sales.
If you have information that could assist in this investigation, or if you are a Dr Reddy's shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (email@example.com) by e-mail or by phone at 619-814-4471. If e-mailing, please include a phone number where you can be reached.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.